New combo aims to outsmart recurrent brain tumors
NCT ID NCT05345002
First seen Oct 31, 2025 · Last updated Jun 19, 2026 · Updated 40 times
Summary
This Phase 2 trial tests a combination of two drugs—all-trans retinoic acid (ATRA) and retifanlimab—in people whose IDH-mutant glioma (a type of brain tumor) has returned after prior treatment. The goal is to see if the combination can boost the immune system to fight the tumor. About 55 participants will receive both drugs for up to two years, and researchers will measure how many tumors shrink or stop growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
All-trans retinoic acid (ATRA) and retifanlimab (a PD-1 inhibitor)
What this could lead to
If successful, this combination could offer a new treatment option for people with recurrent IDH-mutant glioma, potentially slowing tumor growth or shrinking tumors.
What could go wrong
This is an early Phase 2 trial with only 55 participants, so results may not apply to everyone. The drugs may cause side effects or fail to control the cancer long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.